Propylone

Last updated

Propylone
Propylone.svg
Clinical data
Other names3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA
Drug class Monoamine releasing agent; Monoamine reuptake inhibitor
Identifiers
  • 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C13H17NO3
Molar mass 235.283 g·mol−1
3D model (JSmol)
  • CCCNC(C)C(=O)C1=CC2=C(C=C1)OCO2
  • InChI=1S/C13H17NO3/c1-3-6-14-9(2)13(15)10-4-5-11-12(7-10)17-8-16-11/h4-5,7,9,14H,3,6,8H2,1-2H3
  • Key:YFVKHKCZBSGZPE-UHFFFAOYSA-N

Propylone, also known as 3,4-methylenedioxy-N-propylcathinone is a mixed monoamine releasing agent and reupake inhibitor of the cathinone family related to methylone and ethylone. [1]

Contents

It acts specifically as a weak partial serotonin–dopamine releasing agent (SDRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with EC50 Tooltip half-maximal effective concentration (Emax Tooltip maximal efficacy) values for induction of monoamine release of 3,128 nM (30%) for serotonin and 976 nM (20%) for dopamine, and IC50 Tooltip half-maximal inhibitory concentration value for monoamine reuptake inhibition of 2,462 nM for serotonin, 28,540 nM for norepinephrine, and 1,863 nM for dopamine. [1]

The drug was first described in the literature in a 1996 patent by Alexander Shulgin and Peyton Jacob III. [2] It was subsequently characterized more thoroughly by 2015 [1] and was encountered as a novel designer drug in Europe by 2016. [3] [4] [5]

See also

References

  1. 1 2 3 Sakloth F (11 December 2015). Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action. Theses and Dissertations (Ph.D. thesis). Virginia Commonwealth University. doi:10.25772/AY8R-PW77 . Retrieved 24 November 2024– via VCU Scholars Compass.
  2. ↑ WO 1996039133,Jacob III P, Shulgin AT,"Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents.",published 12 December 1996, assigned to Neurobiological Technologies, Inc.
  3. ↑ "EMCDDA–Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA". Europol. 23 October 2018. Retrieved 11 March 2025.
  4. ↑ Liu C, Jia W, Li T, Hua Z, Qian Z (August 2017). "Identification and analytical characterization of nine synthetic cathinone derivatives N-ethylhexedrone, 4-Cl-pentedrone, 4-Cl-α-EAPP, propylone, N-ethylnorpentylone, 6-MeO-bk-MDMA, α-PiHP, 4-Cl-α-PHP, and 4-F-α-PHP". Drug Test Anal. 9 (8): 1162–1171. doi:10.1002/dta.2136. PMID   27863142.
  5. ↑ Pulver B, Fischmann S, Gallegos A, Christie R (December 2024). "EMCDDA framework and practical guidance for naming cathinones". Drug Test Anal. 16 (12): 1409–1435. doi:10.1002/dta.3662. PMC   11635063 . PMID   38389255.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.